Successful Participation at ISPAD 2024
myLoop offers the solution for tailored care for children as well as for an individualised therapy management during exercise. Professor Sabine Hofer and Professor Othmar Moser demonstrated how myLoop powered by CamAPS FX effectively manages a higher day-to-day variation of insulin needs of very young children with type 1 diabetes or during exercise by providing practical guidance on the CamAPS FX system.
Key take-home messages:
myLoop powered by CamAPS FX provides optimal glycaemic management in very young children with type 1 diabetes from onset to minimise early onset diabetes associated with a high lifetime risk of diabetes complications.1
myLoop is valuable and needs to be made available to children with type 1 diabetes at a very young age, as they generally have a higher day-to-day variability of insulin requirements, according to Prof. Sabine Hofer (ISPAD 2024)
myLoop powered by CamAPS FX offers many opportunities to individualise therapy around exercise, which should be adjusted according to the glucose response to exercise.2
Most therapy adjustments should be made 60-120 minutes before exercise, although spontaneous exercise is possible but will result in higher carbohydrate amounts during exercise. However, myLoop is safe to use even during moderate exercise.2
Important for a successful application of myLoop for very young children and adolescents with type 1 diabetes is the education and training of team members, parents and nursery staff.
In our sessions, Professor Sabine Hofer and Professor Othmar Moser explained how AID systems such as myLoop best support very young children and adolescents with type 1 diabetes in their daily glucose management challenges or during exercise.
CamAPS FX delivered sustained and clinically significant improvements in glycaemic management over 18 months in very young children with type 1 diabetes, demonstrating the longer-term safety and glycaemic benefits of hybrid closed-loop therapy in this age group, according to results from an extension phase study.3 Additionally, semi-structured interviews with parents of very young children with type 1 diabetes using hybrid closed-loop systems report a more normal parent/child/family experience.4
Professor Sabine Hofer emphasised that the myLoop system is a well-studied option for young children with diabetes, with the potential to be utilised from the disease onset in very young children. While the remission phase may present certain challenges, myLoop offers a viable approach to managing it.
Professor Othmar Moser presented data demystifying exercise for people with type 1 diabetes and making it available to everyone by showing that myLoop offers numerous opportunities to individualise therapy around exercise.
1. Sundberg F, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers. Pediatr Diabetes. 2022 Dec;23(8):1496-1511. doi: 10.1111/pedi.13427.
2. Moser O, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). 2024. Diabetologia & Hormone Research in Paediatrics – in press.
3. Ware J, et al. Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial. Diabetes Care 2024; dc241313. doi.org/10.2337/dc24-1313
4. Kimbell B, et al. Parents' experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: Qualitative study. Diabetes Res Clin Pract. 2022 May;187:109877. doi: 10.1016/j.diabres.2022.109877.
Disclaimer
The product images are for illustrative purposes only.
mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries.
CamAPS is a registered trademark of CamDiab Ltd.
Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license.Other trademarks are the property of their respective owners.
myLoop with Freestyle Libre3/Libre 3 Plus: The innovations described are available in selected countries and expanding to further countries soon. Expansion is contingent upon local regulatory approval.Insulin pumps and Automated Insulin Delivery (AID) systems can improve glucose management but do not remove the risk of diabetic ketoacidosis (DKA). Because these systems use only rapid-acting insulin, any interruption in insulin delivery (e.g., infusion-set failure, occlusion, empty reservoir, or device malfunction) can rapidly lead to ketosis and DKA, even if glucose levels are not markedly elevated.
Healthcare professionals should ensure that users understand the risk of DKA associated with pump and AID therapy, particularly in situations where insulin delivery may be interrupted. Users should be trained to recognise and troubleshoot delivery issues promptly, know when and how to check for ketones and seek urgent medical assistance. Advise to always keep a reliable backup method of insulin delivery available.This information is provided for general educational purposes and is intended for healthcare professionals. It does not replace individual clinical judgement or patient-specific medical advice.